Nurix Therapeutics (NRIX) Director P Sells $529K of Stock

Julia P. Gregory, a director at Nurix Therapeutics, Inc. (NasdaqGM: NRIX), sold 22,583 shares on October 14, 2026, for about $528,528 at a price of $23.40 per share. This sale comes as the company's stock trades at $24.89, down from its previous close of $25.44 on the day of the sale.

Inside Gregory's Trade

Gregory's transaction reflects ongoing activity in the biotech company, which focuses on developing therapies for cancer and other diseases. This was not a planned sale, and it adds to the recent trend of insider transactions as other executives have also sold shares. Notably, Chief Scientific Officer Gwenn Hansen sold 1,452 shares just a day later on October 15, also at a price of $25.00.

Other Institutional Activity in Nurix

In the latest reporting period, several institutional investors adjusted their positions in Nurix. For instance, Vestal Point Capital, LP increased its holdings by 1,550,202 shares, totaling 8,050,000 shares worth about $199.6 million. Meanwhile, Deep Track Capital, LP added 1,391,458 shares, growing its stake to 7,736,455 shares valued at approximately $191.8 million. On the other hand, BlackRock Inc. trimmed its position by 155,306 shares, ending with 8,770,349 shares valued at approximately $217.4 million.

Nurix Therapeutics, Inc. Stock Down 0.2%

Currently, Nurix shares are trading at $24.89, which is below their 52-week high of $28.23 and closer to their 52-week low of $8.20. The stock has a forward P/E ratio of -23.85, indicating that it is not currently profitable. The shares have been fluctuating around their 50-day moving average of $25.20.

Recent Earnings

In its latest earnings report, Nurix reported revenues of $36.8 million, showing a decline compared to the previous year. The company has experienced revenue growth challenges, with a net margin of 0.0% and an EPS of -3.46. The next earnings report is scheduled for October 8, 2026.

Insider Buying and Selling at Nurix Therapeutics, Inc.

Besides Gregory's sale, other insiders have recently sold shares as well. Gwenn Hansen, the Chief Scientific Officer, sold 1,452 shares at $25.00 on October 15, totaling $36,300. Additionally, another officer, Gwenn Hansen M, sold 1,452 shares on the same day, although the transaction price was not disclosed. Christine Ring, an officer, sold 5,787 shares on September 2, valued at approximately $149,072.

Analysts Set New Price Targets

Recently, analysts have maintained their positive outlook for Nurix. On October 16, HC Wainwright & Co. kept a 'Buy' rating with a target price of $36.00, while RBC Capital maintained an 'Outperform' rating with a target of $35.00 on October 13. Oppenheimer also maintained its 'Outperform' rating with a target price of $32.00 on the same day. The average analyst price target sits at about $33.93 with 14 opinions.

About Nurix Therapeutics

Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Brisbane, CA. The company develops small molecule and antibody therapies aimed at treating cancer and inflammatory conditions. The recent insider transactions may reflect company sentiments as it navigates its business strategy with potential market challenges ahead.

Bottom Line

Investors should keep an eye on Nurix's upcoming earnings date on October 8, 2026, and monitor further insider trading activity. The recent 13F filings provide insight into how institutional investors are positioning themselves amid market fluctuations. The activity in shares and analyst ratings suggests ongoing interest in the company despite recent challenges in revenue growth.